trial
as of 2026-07-01A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
NCTId NCT07038876
at a glance
Phase 2 · Active Not Recruiting
Enrollment 307 (actual)
Sponsored by MapLight Therapeutics
Primary completion 2026-08
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Active Not Recruiting
Enrollment
307 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-06-27
Primary completion
2026-08
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Sponsors
MapLight TherapeuticsLead Sponsor
Investigators
1
MapLight TherapeuticsStudy Director
Sites
24 total
Little Rock, United StatesBellflower, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesLos Angeles, United StatesMontclair, United StatesOrange, United StatesRiverside, United StatesSan Diego, United StatesSherman Oaks, United StatesTorrance, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
307
Phase
PHASE2
Primary Completion Date
2026-08
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
drug
drug
lead_sponsor
company
indication
investigator
person